Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GOVX
GOVX logo

GOVX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy GeoVax Labs Inc (GOVX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.170
1 Day change
-5.65%
52 Week Range
34.750
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

GeoVax Labs Inc (GOVX) is not a suitable buy for a beginner investor with a long-term strategy at this time. The company's financial performance is weak, with no revenue in the latest quarter, and its stock is exhibiting bearish technical indicators. Additionally, analysts have downgraded the stock due to elevated near-term execution risks and limited catalysts. There are no significant positive catalysts or trading signals to justify a buy recommendation.

Technical Analysis

The stock exhibits bearish technical indicators. The MACD is above zero but positively contracting, RSI is neutral at 38.673, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 1.265, with resistance at 1.37 and support at 1.161.

Positive Catalysts

  • NULL identified. No recent news or significant trading trends from hedge funds or insiders. Gross margin remains at 100%, but this is not supported by revenue growth.

Neutral/Negative Catalysts

  • The company reported zero revenue in Q3 2025, a significant YoY decline. Analysts have downgraded the stock due to limited near-term catalysts and tightening capital resources. The stock's EPS dropped significantly (-65.68% YoY), and the company continues to post negative net income.

Financial Performance

GeoVax Labs reported zero revenue in Q3 2025, down -100% YoY. Net income improved slightly to -$6,318,914 (up 8.66% YoY), but the EPS dropped significantly to -7.79 (-65.68% YoY). Gross margin remained at 100%, but this is not indicative of operational success given the lack of revenue.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

D. Boral Capital analyst downgraded the stock to Hold from Buy, citing a constrained near-term outlook, elevated execution risks, and limited catalysts. No price target was provided.

Wall Street analysts forecast GOVX stock price to rise
2 Analyst Rating
Wall Street analysts forecast GOVX stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.170
sliders
Low
10
Averages
12
High
14
Current: 1.170
sliders
Low
10
Averages
12
High
14
Roth Capital
Buy
to
Buy
downgrade
$14 -> $10
AI Analysis
2026-04-17
New
Reason
Roth Capital
Price Target
$14 -> $10
AI Analysis
2026-04-17
New
downgrade
Buy
to
Buy
Reason
Roth Capital lowered the firm's price target on GeoVax Labs to $10 from $14 and keeps a Buy rating on the shares. GeoVax ended Q4 with limited cash and is advancing key programs, including a Phase 3 trial for GEO-MVA expected to begin in 2H26 and continued progress for GEO-CM04S1 in immunocompromised patients, the analyst tells investors in a research note. The company also plans to initiate a 2H26 trial of Gedeptin in combination with pembrolizumab for head and neck cancer, following encouraging external study results, the firm says.
D. Boral Capital
Jason Kolbert
Buy -> Hold
downgrade
2026-02-19
Reason
D. Boral Capital
Jason Kolbert
Price Target
2026-02-19
downgrade
Buy -> Hold
Reason
D. Boral Capital analyst Jason Kolbert downgraded GeoVax Labs to Hold from Buy without a price target. The firm says the company is facing a "more constrained" near-term outlook with limited catalysts and tightening capital resources. While the company continues to advance GEO-MVA as a potential diversification solution within the mpox vaccine landscape, its near-term execution risk is elevated, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GOVX
Unlock Now

People Also Watch